All of the following statements about the use of spironolactone in CHF are true except:
It should be administered in low doses to prevent hyperkalemia It affords prognostic benefit in severe heart failure over and above that afforded by ACE inhibitors It helps to overcome the refractoriness to thiazides It affords rapid symptomatic relief in CHF patients